{"id":458146,"date":"2021-03-15T17:36:17","date_gmt":"2021-03-15T21:36:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458146"},"modified":"2021-03-15T17:36:17","modified_gmt":"2021-03-15T21:36:17","slug":"logicbio-therapeutics-reports-full-year-2020-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/logicbio-therapeutics-reports-full-year-2020-financial-results-and-provides-business-update\/","title":{"rendered":"LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

– First patient for Phase 1\/2 SUNRISE trial expected to be enrolled in early 2021<\/h2>\n

-Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date<\/h2>\n

-New Chief Scientific and Chief Financial Officers recently added to Executive Team<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n

\n

\n LEXINGTON, Mass.<\/span>, March 15, 2021<\/span> \/PRNewswire\/ —\u00a0LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the year ended December 31, 2020<\/span> and provided a business update. <\/p>\n

“The fourth quarter of 2020 marked a continuation of strong momentum for LogicBio which has also extended into 2021,” said Frederic Chereau<\/span>, President and CEO. “Most notably, we continue to anticipate enrolling the first patient in our SUNRISE Trial of LB-001 for the treatment of MMA in the very near future. We expect this event will be followed by additional enrollments soon after and allow us to begin to generate data regarding the safety, and clinical impact of treatment with LB-001 for these children. In addition, we also recently announced that we have extended our collaboration with the Children’s Medical Research Institute of Australia<\/span> to continue to develop sAAVy\u2122<\/span>, our next generation capsids platform, which has already yielded novel liver-tropic capsids that we believe are superior to ones that are currently used in the clinic. We believe these capsids will allow LogicBio to continue to expand its gene editing platform, GeneRide, and potentially initiate gene therapy programs, either alone or in collaboration with strategic partners. We look forward to providing further updates on these programs throughout 2021.” Mr. Chereau concluded by saying, “I am also very excited by the new members we have added to our team. Both Mariana Nacht<\/span>, our new CSO, and Cecilia Jones<\/span>, our new CFO, bring a wealth of biotech industry experience, and I am delighted they have chosen to join LogicBio as we move into this exciting next phase of progress.” <\/p>\n

\n Anticipated LogicBio Milestones for 2021:<\/b>\n <\/p>\n

\n LB-001 for MMA<\/b>\n <\/p>\n